Millennium Management LLC Boosts Holdings in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)

Millennium Management LLC increased its holdings in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 727.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 802,607 shares of the specialty pharmaceutical company’s stock after purchasing an additional 705,600 shares during the period. Millennium Management LLC owned 2.37% of AMAG Pharmaceuticals worth $9,270,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of AMAG. Permanens Capital L.P. grew its holdings in AMAG Pharmaceuticals by 53.0% during the 3rd quarter. Permanens Capital L.P. now owns 407,811 shares of the specialty pharmaceutical company’s stock valued at $4,710,000 after buying an additional 141,311 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of AMAG Pharmaceuticals by 12.0% during the third quarter. Russell Investments Group Ltd. now owns 101,700 shares of the specialty pharmaceutical company’s stock worth $1,175,000 after acquiring an additional 10,900 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of AMAG Pharmaceuticals by 11.8% during the third quarter. California Public Employees Retirement System now owns 80,327 shares of the specialty pharmaceutical company’s stock worth $928,000 after acquiring an additional 8,474 shares during the last quarter. State of Tennessee Treasury Department grew its stake in AMAG Pharmaceuticals by 10.4% during the third quarter. State of Tennessee Treasury Department now owns 25,899 shares of the specialty pharmaceutical company’s stock valued at $299,000 after acquiring an additional 2,435 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in AMAG Pharmaceuticals by 5.0% during the third quarter. Rhumbline Advisers now owns 114,850 shares of the specialty pharmaceutical company’s stock valued at $1,327,000 after acquiring an additional 5,457 shares in the last quarter.

Shares of AMAG opened at $11.07 on Friday. The company’s fifty day moving average is $10.53 and its 200 day moving average is $10.35. AMAG Pharmaceuticals, Inc. has a fifty-two week low of $6.81 and a fifty-two week high of $18.39. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.53 and a current ratio of 1.67.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Friday, November 1st. The specialty pharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.19). AMAG Pharmaceuticals had a negative net margin of 88.54% and a negative return on equity of 34.59%. The business had revenue of $84.13 million for the quarter, compared to analysts’ expectations of $88.25 million. During the same period in the previous year, the company earned $0.89 EPS. AMAG Pharmaceuticals’s revenue for the quarter was down 31.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that AMAG Pharmaceuticals, Inc. will post -3.83 earnings per share for the current year.

Several brokerages have commented on AMAG. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 23rd. ValuEngine downgraded shares of AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 3rd. Piper Jaffray Companies lowered AMAG Pharmaceuticals from a “neutral” rating to an “underweight” rating and cut their price objective for the company from $9.00 to $6.00 in a research report on Wednesday, October 30th. Barclays reaffirmed a “buy” rating and issued a $14.00 target price (down from $16.00) on shares of AMAG Pharmaceuticals in a report on Sunday, November 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $13.28.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Story: Why is the price-sales ratio important?

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.